(±)-FTC

N/A

Report date: 2022/11/25 17:30:32
NME

Base Information

Drug Name(±)-FTC
Drug Alias NameRacivirRacemic-FTCPSI-5004RCV(±)-FTC
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHuman immunodeficiency virus type 1 reverse transcriptase inhibitors
TargetsHuman immunodeficiency virus type 1 reverse transcriptase
Therapy Area/IndicationsHIV Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryPanamaUnited StatesMexico +[4] 
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPharmasset Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPharmasset Ltd
Active IndicationsN/A
Inactive IndicationsHIV Infections

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBank